Sarah C Oltmann1, Amal Y Alhefdhi2, Mohammad H Rajaei3, David F Schneider3, Rebecca S Sippel3, Herbert Chen4. 1. Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA. sarah.oltmann@utsouthwestern.edu. 2. Department of Surgery, The King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. 3. Department of Surgery, University of Wisconsin, Madison, WI, USA. 4. Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Abstract
PURPOSE: Antiplatelet and/or anticoagulant medication use is common. Abstinence a week before surgery may still result in altered hemostasis. The study aim was to report on perioperative antiplatelet and anticoagulant use in thyroidectomy and parathyroidectomy patients, and to determine the association with postoperative hematoma (POH) rates. METHODS: Retrospective review of a prospective endocrine surgery database was performed. Procedure extent was defined as unilateral, bilateral, or extensive. Antiplatelets were categorized as none, 325 mg aspirin (ASA), <325 mg ASA, clopidogrel, or other. Anticoagulants were categorized as none, oral, or injectable. RESULTS: A total of 4514 patients were identified. POH developed in 22 patients (0.5 %). Rates were similar between age, gender, and reoperative status. POH were seven times more common after thyroidectomy (0.8 vs. 0.1 %, p < 0.01). Unilateral procedures had lower POH rates than bilateral or extensive (0.1 vs. 0.9 vs. 0.8 %, p < 0.01). POH rates in patients receiving 325 mg ASA (0.8 %) or clopidogrel (2.2 %) were much higher than patients not receiving antiplatelets (0.5 %) or receiving <325 mg ASA (0.1 %, p = 0.04). Oral anticoagulants (2.2 %) and injectable anticoagulants (10.7 %) had much higher POH rates than patients not receiving anticoagulants (0.4 %, p < 0.01). Target organ, patient gender, procedure extent, antiplatelet use, and anticoagulant use were included on logistic regression to determine association with POH. Bilateral procedures, thyroidectomy, clopidogrel, oral, and injectable anticoagulants were all independently associated with POH. CONCLUSIONS: POH occur more frequently after thyroidectomy and during bilateral procedures. Patients requiring clopidogrel or any anticoagulant coverage are at much higher risk for POH. These higher-risk patients should be considered for observation to ensure prompt POH recognition and intervention.
PURPOSE: Antiplatelet and/or anticoagulant medication use is common. Abstinence a week before surgery may still result in altered hemostasis. The study aim was to report on perioperative antiplatelet and anticoagulant use in thyroidectomy and parathyroidectomy patients, and to determine the association with postoperative hematoma (POH) rates. METHODS: Retrospective review of a prospective endocrine surgery database was performed. Procedure extent was defined as unilateral, bilateral, or extensive. Antiplatelets were categorized as none, 325 mg aspirin (ASA), <325 mg ASA, clopidogrel, or other. Anticoagulants were categorized as none, oral, or injectable. RESULTS: A total of 4514 patients were identified. POH developed in 22 patients (0.5 %). Rates were similar between age, gender, and reoperative status. POH were seven times more common after thyroidectomy (0.8 vs. 0.1 %, p < 0.01). Unilateral procedures had lower POH rates than bilateral or extensive (0.1 vs. 0.9 vs. 0.8 %, p < 0.01). POH rates in patients receiving 325 mg ASA (0.8 %) or clopidogrel (2.2 %) were much higher than patients not receiving antiplatelets (0.5 %) or receiving <325 mg ASA (0.1 %, p = 0.04). Oral anticoagulants (2.2 %) and injectable anticoagulants (10.7 %) had much higher POH rates than patients not receiving anticoagulants (0.4 %, p < 0.01). Target organ, patient gender, procedure extent, antiplatelet use, and anticoagulant use were included on logistic regression to determine association with POH. Bilateral procedures, thyroidectomy, clopidogrel, oral, and injectable anticoagulants were all independently associated with POH. CONCLUSIONS:POH occur more frequently after thyroidectomy and during bilateral procedures. Patients requiring clopidogrel or any anticoagulant coverage are at much higher risk for POH. These higher-risk patients should be considered for observation to ensure prompt POH recognition and intervention.
Authors: A Bergenfelz; S Jansson; A Kristoffersson; H Mårtensson; E Reihnér; G Wallin; I Lausen Journal: Langenbecks Arch Surg Date: 2008-07-17 Impact factor: 3.445
Authors: S Coiro; F M Frattaroli; F De Lucia; E Manna; F Fabi; J M Frattaroli; G Pappalardo Journal: Langenbecks Arch Surg Date: 2015-01-13 Impact factor: 3.445
Authors: Nicholas Clark; David F Schneider; Sara Vrabec; Philip S Bauer; Herbert Chen; Rebecca S Sippel Journal: J Surg Res Date: 2013-05-09 Impact factor: 2.192
Authors: Giovanni Docimo; Salvatore Tolone; Roberto Ruggiero; Gianmattia del Genio; Luigi Brusciano; Angela Pezzolla; Gianpaolo Jannelli; Alfonso Bosco; Domenico Parmeggiani; Cosmo Cosenza; Paolo Limongelli; Ludovico Docimo Journal: Int J Surg Date: 2014-06-08 Impact factor: 6.071
Authors: Ulrich Wirth; Josefine Schardey; Magdalena Bonleitner; Desiree Weber; Thomas von Ahnen; Roland Ladurner; Joachim Andrassy; Jens Werner; Hans Martin Schardey; Stefan Schopf Journal: Gland Surg Date: 2022-04
Authors: Ralph F Staerkle; Henry Hoffmann; Ferdinand Köckerling; Daniela Adolf; Reinhard Bittner; Philipp Kirchhoff Journal: Surg Endosc Date: 2018-02-28 Impact factor: 4.584
Authors: Sadaf Mohtashami; Keith Richardson; Veronique-Isabelle Forest; Alex Mlynarek; Richard J Payne; Michael Tamilia; Marc P Pusztaszeri; Michael P Hier; Nader Sadeghi; Marco A Mascarella Journal: Ann Otol Rhinol Laryngol Date: 2021-06-01 Impact factor: 1.547